From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. HIV/AIDS Clinical Care>
  4. Meetings

HIV/AIDS Clinical Care: Meetings

Some content may require paid access to the site. Subscribe or purchase a seven-day site pass for the full text of all our clinical perspectives on medical journal articles, guidelines, and news.


to
Items 1-10 of 206 are shown

Report from the 20th Conference on Retroviruses and Opportunistic Infections

Our physician-editors highlight the most clinically relevant findings from the 2013 meeting in Atlanta.

No Major Breakthroughs in Biomedical Prevention

Results presented at CROI 2013 underscore some of the barriers to pre-exposure prophylaxis.

The Road to HIV Cure: Twists and Turns

At CROI 2013, presentations encompassed a range of topics, from possible cure in an infant to sobering data on the size of the HIV reservoir.

HCV Treatment — On the Threshold

Interferon-free regimens stole the show.

Improving ART — the Pipeline Remains Open in 2013

At CROI 2013, investigators presented findings from a phase III study of dolutegravir, clinical data on tenofovir alafenamide (TAF), and initial data on a new NNRTI (MK-1439).

Progress in Understanding and Addressing the HIV Cascade of Care

Encouraging data were presented at CROI 2013, but many challenges remain.

Causes of Death Changing in HIV

Although AIDS remains the leading cause of death in HIV-infected individuals in developed countries, deaths from non–AIDS-defining malignancies are creeping upward, according to a study presented at AIDS 2012.

HIV and Accelerated Aging: Stay Tuned

Many chronic conditions traditionally associated with aging occur prematurely in HIV-positive patients, according to data presented at AIDS 2012.

The Cascade of HIV Care in the U.S.

Only 25% of HIV-infected people in the U.S. achieve virologic suppression, and that number is even lower for racial/ethnic minorities, according to data presented at AIDS 2012.

The Trade-Offs of Branded Versus Generic First-Line ART

A modeling analysis presented at AIDS 2012 indicated that switching patients from a branded regimen to a predominantly generic one would decrease annual HIV treatment costs in the U.S. by almost one billion dollars but would result in a modest decrease in estimated survival.

Items 1-10 of 206 are shown

to

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?





Copyright © 2013. Massachusetts Medical Society. All rights reserved.